Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

ENDRA Life Sciences (NDRA) Equity Average (2017 - 2025)

ENDRA Life Sciences has reported Equity Average over the past 5 years, most recently at $12.0 million for Q4 2021.

  • Quarterly Equity Average rose 127.91% to $12.0 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Dec 2021, up 127.91% year-over-year, with the annual reading at $9.0 million for FY2021, 50.49% up from the prior year.
  • Equity Average was $12.0 million for Q4 2021 at ENDRA Life Sciences, down from $14.1 million in the prior quarter.
  • Over five years, Equity Average peaked at $16.4 million in Q2 2021 and troughed at -$1.1 million in Q1 2017.
  • The 5-year median for Equity Average is $3.4 million (2017), against an average of $5.3 million.
  • Year-over-year, Equity Average tumbled 90.08% in 2018 and then surged 838.63% in 2021.
  • A 5-year view of Equity Average shows it stood at $6.2 million in 2017, then plummeted by 53.46% to $2.9 million in 2018, then increased by 6.44% to $3.1 million in 2019, then soared by 70.43% to $5.3 million in 2020, then surged by 127.91% to $12.0 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Equity Average are $12.0 million (Q4 2021), $14.1 million (Q3 2021), and $16.4 million (Q2 2021).